Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2023
Reporting Period: The filing announces financial results for the three and nine months ended September 30, 2023.
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. The filing states that these details are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this report.
Material Changes
The filing text does not provide specific figures or descriptions of material changes versus prior periods. Investors must refer to the referenced press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Management Commentary
Conference Call: Management scheduled a conference call for November 7, 2023, at 8:00 AM ET to discuss the results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific revenue, net income, and cash flow figures for the quarter and nine months ended September 30, 2023.
- Verify year-over-year and quarter-over-quarter growth rates in the referenced press release.
- Check for any updated forward-looking guidance or outlook provided during the November 7, 2023, conference call.
- Confirm the company's liquidity position and debt levels as detailed in the full financial statements referenced in the press release.